Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Executives from 7 drug companies appear before the Senate. Photo: Win McNamee/Getty Images

Drug companies have cheered the Trump administration's proposed crackdown on industry middlemen, but some hedged this morning when asked whether that plan would cause them to lower their prices.

The big picture: Pharmaceutical executives have stayed firmly on message even amid some tough questioning from the Senate Finance Committee.

What they're saying: Several lawmakers have taken a tough tone against the 7 executives testifying this morning about drug prices.

  • Sen. Ron Wyden (D-Ore.), for example, said AbbVie "protects the exclusivity of Humira like Gollum with his ring."
  • The pharmaceutical executives in attendance responded with many of the industry's standard arguments, including broadsides against pharmacy benefit managers and the drug rebate system PBMs rely on.

Between the lines: The Trump administration has proposed eliminating those PBM rebates in Medicare and Medicaid, saying that will also translate into lower sticker prices. Finance Chairman Chuck Grassley (R-Iowa) asked the executives whether they would, in fact, lower prices as a result of the rebate proposal.

  • AstraZeneca CEO Pascal Soriot and Merck CEO Ken Frazier both said their companies would lower drug prices if the rebate rule was applied to both the Medicare and commercial insurance markets. For now, it doesn't apply to commercial insurance.
  • Others said they similarly supported the rule, but hedged by saying costs would be lower for patients when they pick up the drug at the pharmacy — not necessarily that the health care system as a whole would be paying less.

Go deeper

D.C.'s building boom grinds to a halt

Illustration: Brendan Lynch/Axios

The decades-long building boom that remade Washington D.C. is screeching to a halt, undone by broader construction trends and the legacy of the post-pandemic workplace.

Why it matters: Dizzying construction has reshaped the city, reinvigorated downtown and created bustling new communities. 

Facebook fights for its image

Illustration: Annelise Capossela/Axios

Facebook is ditching apologies and taking a more combative stance against its critics as it faces a new barrage of negative coverage and leaked internal reports.

Driving the news: As part of the new posture, Facebook started testing placing positive messages about itself in users' News Feeds last month, according to a New York Times story Tuesday.

2 hours ago - Politics & Policy

Charter schools boomed during the pandemic

Expand chart
Data: National Alliance for Public Charter Schools; Map: Sara Wise/Axios

Charter schools picked off hundreds of thousands of public school students across the U.S. during the pandemic, according to a new analysis from the National Alliance for Public Charter Schools.

Why it matters: The pandemic has weakened America's public education system, as Zoom classes, teacher fatigue and student disengagement take their toll. And that hobbled system is shedding students to charter schools, private schools and homeschooling.